1 / 162

Atherosclerotic and Ischemic Heart Disease

Atherosclerotic and Ischemic Heart Disease. Howard L. Sacher, D.O. Long Island Cardiology and Internal Medicine. Teaching Objectives. To understand the pathogenesis of atherosclerosis and assess coronary blood flow reserve To properly diagnose and manage stunned and hibernating myocardium

Download Presentation

Atherosclerotic and Ischemic Heart Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Atherosclerotic and Ischemic Heart Disease Howard L. Sacher, D.O. Long Island Cardiology and Internal Medicine

  2. Teaching Objectives • To understand the pathogenesis of atherosclerosis and assess coronary blood flow reserve • To properly diagnose and manage stunned and hibernating myocardium • To make appropriate decisions in non-invasive testing processes and medical management of chronic ischemic heart disease, including the use of coronary angioplasty and coronary artery bypass grafts (CABG).

  3. Teaching Objectives (cont) • To manage the secondary prevention of coronary artery disease • To manage unstable angina, variant angina, and silent myocardial ischemia • To understand cardiac management considerations in women

  4. Coronary Heart Disease • One million deaths among Americans are the result of CAD • More than two out of every five deaths are the result of CAD • Of the current US population, 1 in 4 suffer from some form of CVD • Prevalence increases markedly with age

  5. Reduction in Mortality of CAD Deaths • Reduction of risk factors • Hypertension • Diabetes Mellitus • Hyperlipidemia • Inprovement of socioeconomic circumstances • New methods of diagnosis and treatment • Enhanced access to care

  6. Vascular Injury • Vascular endothelial injury is a critical initiating event in atherogenesis. It leads to • Lipid accumulation • Release of various growth factors • Migration and proliferation of smooth muscle cells

  7. Pathophysiology • Classification of vascular injury is divided into 3 types: • Type I Functional alteration • Type II  Endothelial and Intimal damage, the internal elastic lamina is preserved • Type III  Deep injury involving the intima and media. The lamina is not preserved

  8. After Type I injury the endothelium’s ability to release intrinsic relaxing substances

  9. Proposed scenario of EDRF and Endothelin during ischemic syndromes

  10. ACh decreases as risk factors increase, decreasing the smooth muscles’ ability to relax

  11. Endothelium • Decrease vasodilitory substances such as EDRF (nitric oxide) with associated anti-proliferative properties • Releasing vasoconstriction substances such as endothelin, with associated migration properties • Critical balance between nitric oxide and endothelin may be major determinant in regulatory system and regional hemodynamic function and cellular proliferation

  12. CAD Risk Factors • Age • Male/Female • Obesity • Smoking • Hypertension • Diabetes Mellitus • Family History • Hyperlipidemia

  13. Approach to Patients with CAD • History • Physical Exam • Treatment • EKG • Cardiac enzymes – CPK-MB, Troponin • Admit to hospital

  14. Approach to Patients with CAD (cont) • Stress test • Gradual exercise stress test • Regular stress test, exercise or pharmacological • Stress echo or pharmacological • Coronary and cardiac catheterization – angioplasty • Percutaneous transluminal coronary angioplasty (PTCA) with stenting • Coronary artery bypass graft (CABG) surgery

  15. Smooth Coronary artery segment that shows EDRF dependent dilation to ACh will also dilate with exerciseBut when evaluating coronary segments that were irregular and stenosed, they did not show EDRF dependent dilation to ACH. These did not dilate with exercise

  16. Adenosine • Thought to act on the coronary vasculature by stimulating the Adenosine A2 receptors on the smooth muscles. • Adenosine crosses the endothelial barriers to stimulate the Endothelial Independent Pathway for vasodilatation

  17. Adenosine • Is thought to act on the coronary vasculature via stimulation of the adenosine A2 receptors on smooth muscle cells, which activates adenylate cyclase to produce cyclic adenosine monophosphate (cAMP) and smooth muscle relaxation. At pharmacological doses , adenosine can cross the endothelium and stimulate the receptors on the smooth muscle directly in an endothelium-independent mechanism. Adenosine also acts predominantly on vessels less than 150 micrometers in diameter and therefore mainly assesses its changes in the coronary resistance vessels

  18. Nitroglycerine (NTG) • A vasodilator that acts directly on smooth muscle through a cGMP mechanism – non endothelial dependant vascular response. Because coronary microvessels contain the enzyme needed to convert nitroglycerine into nitric oxide, nitroglycerine creates a dose related dilatation of coronary vessels > 200 microns in diameter

  19. Coronary Stenosis • As coronary stenosis progresses, the microvascular dilates to compensate • During increased myocardial demand, the capacity of the microvascular to dilate further is limited (vessels are already maximally dilated) resulting in myocardial ischemia.

  20. Treatment • Nitrates – • Dilate vessels and improve flow • Reduce afterload and preload • Preload = volume – end diastolic volume (EDV) • Afterload = amount of pressure generated to push blood out of the heart • Contractility can be improved by decreasing preload and afterload but if too vigorous will decrease contractility • In La Place’s Law, Tension = Pressure X Resistance • As the preload pressure decreases and radius goes down, wall tension is less and, therefore, heart does not need to push as hard

  21. Treatment (cont) • Beta-Blockers • Decreases contractility and myocardial oxygen demand by decreasing wall tension • ACE- I • Lipid Lowering • Aspirin

  22. Stunned and Hibernating Myocardium • Hibernating Myocardium • Areas of myocardium supplied by severely stenosed coronary arteries that over time develop impaired left ventricular contractility despite the presence of viable myocardium • Clinical importance is that if blood flow is improved to these areas, there is improvement in contractility, which is associated with improvement of heart failure symptoms and improved survival

  23. Stunned and Hibernating Myocardium (cont) • Stunned Myocardium • Areas of myocardium that develop post ischemic dysfunction in the absence of, or with, minimal necrosis • Stunning is seen following acute myocardial infarction or repeat episodes of angina

  24. Stunned and Hibernating Myocardium (cont) • Both stunned and hibernating myocardium are characterized by severe wall motion abnormalities in the presence of living or viable myocardium • Dysfunctional stunned myocardium is more acute and will regain function over time without intervention • Hibernating myocardium is more chronic and rigorous restoration of blood flow by revascularlization (CABG / PCTA with stenting) is needed in order to restore contractility

  25. Stunned and Hibernating Myocardium (cont) • Stunning can follow hibernation if the residual stenosis is sufficiently severe. If the area is necrotic, revascular-ization will not improve ventricular function.

  26. The hypokinetic inferior and akinetic apical wall is shown to improve several months after revascularization

  27. Bayes’ Theorum: Non-Invasive Testing • Predictability of a given test depends on the prevalence of the disease in the study population. Low likelihood, low probability; high likelihood, high probability. Therefore, routine testing on asymptomatic individuals without significant cardiac risk factors should be avoided, because such tests will result in more false positives than true positives. Diagnostic invasive testing is best applied to the group with an intermediate probability of coronary artery disease such as patients with multiple risk factors and atypical chest pain or patients with typical chest pain but no risk factors.

  28. Who Benefits from Diagnostic Testing from this Last Graph? • A Pt with a low pre-test probablity of disease will continue to have a low likelihood of disease regardless of a (-) test • A Pt with a high pre-test probability of disease will continue to have a high likelihood of disease regardless of a (-) test • Diagnostic testing is most beneficial for those Pt’s with intermediate probability for disease

  29. Normal MIBI – uniform tracer uptake globally on SA slices

  30. Normal VLA slices

  31. Normal HLA slices of the same patient

  32. Patient with Basilar Septal ischemia evidenced by decreased tracer uptake at STRESS with increased uptake at REST

  33. Pt also has some apical thinning

  34. With a completely reversible Septal wall toward the Anterior segments of the ventricle on HLA

  35. Ischemia that is a result of Stress is dynamic with cascade of events, pain and ECG changes are seen late in the game

  36. The Role of Diagnostic Testing • Once the diagnosis of CAD has been made, or the patient has stable anginal symptoms, non-invasive testing remains useful in stratifying patients into high risk and low risk groups, monitoring changes in patient status and in drug management.

More Related